Circular RNA & Chemerin in Breast Cancer Patient

Status Not yet recruiting

Clinical Trial Summary

This study aimed to evaluate the role of serum chemerin as a biomarker of breast cancer. and To investigate the diagnostic value of hsa_circ_0001785 (Circ-ELP3) and hsa_circ_100219 (Circ-FAF1) in serum samples of breast cancer patients to find out whether these circRNAs can utilize as a diagnostic and prognostic biomarker for human breast cancer assessment and make Correlation between serum chemerin levels , serum Circ-FAF1 , serum CircELP3 and classical tumor markers (CEA + CA15-3). andTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

Clinical Trial Description

Breast cancer is the most common cancer among women and despite advances in therapy over the past few decades, drug resistance, recurrence, metastasis and the heterogeneity of the cancer continue to be a problem in successful management of the diseases(Hong et al ,2019) . Circular RNAs (CircRNAs) are single-stranded, covalently closed RNA molecules that are ubiquitous across species ranging from viruses to mammals(Zhou et al 3 .,2020). circRNAs can be divided into two categories including coding and noncoding circRNAs(Li et al., 2019) A new subtype of RNAs is circular RNAs, single-strand RNA molecules with less than 100 to more than 4,000 nucleotides (Lu et al., 2016) and a covalently closedloop structure. These molecules are produced through a backsplicing mechanism, in which the downstream 5'-end of the splice donor joins the upstream 3'-end splice acceptor and forms a product with a circular structure (wang et al., 2017). Chemerin is a leukocyte chemoattractant widely expressed in many tissues and is known to recruit innate leukocytes. Recently, more and more studies focus on the relationship between chemerin and cancers and found that chemerin acts an essential role in cancers.(Shin et al,2018) Chemerin expression is different depending on the tumor type (Zhang Y et al, 2013) the clinical significance of chemerin in breast cancer has been only reported by a very limited number of studies (EL Sagheer et al,2018). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05771337
Study type	Observational
Source	Assiut University
Contact	sandy nashat sorial
Phone	01200693648
Email	sandybsbsa@yahoo.com
Status	Not yet recruiting
Phase
Start date	October 2023
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04681911` - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT04890327` - Web-based Family History Tool	N/A
Terminated	`NCT04066790` - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer	Phase 2
Completed	`NCT03591848` - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility	N/A
Recruiting	`NCT03954197` - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients	N/A
Terminated	`NCT02202746` - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer	Phase 2
Active, not recruiting	`NCT01472094` - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn	`NCT06057636` - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study	N/A
Completed	`NCT06049446` - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting	`NCT05560334` - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations	Phase 2
Active, not recruiting	`NCT05501769` - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer	Phase 1
Recruiting	`NCT04631835` - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer	Phase 1
Completed	`NCT04307407` - Exercise in Breast Cancer Survivors	N/A
Recruiting	`NCT03544762` - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation	Phase 3
Terminated	`NCT02482389` - Study of Preoperative Boost Radiotherapy	N/A
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Completed	`NCT00226967` - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting	`NCT06006390` - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06019325` - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy	N/A
Recruiting	`NCT06037954` - A Study of Mental Health Care in People With Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Circular RNA and Chemerin in Breast Cancer Patient

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms